Download Free Medical Small Cell Lung Cancer (SCLC): Diagnosis Treatment and Natural History PowerPoint Presentation

Small Cell Lung Cancer (SCLC): Diagnosis Treatment and Natural History PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "Small Cell Lung Cancer (SCLC): Diagnosis, Treatment and Natural History" provides us lung cancer epidemiology.

Tags : Small Cell Lung Cancer, SCLC, Pathology, Tumor markers, Genetics, Clinical course, Staging, Treatment

Published on : Apr 28, 2021 | Views : 1841 | Downloads : 9

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Small Cell Lung Cancer (SCLC): Diagnosis, Treatment and Natural History Gary L.Weinstein M.D.
Slide 2-

SCLC Lung cancer epidemiology SCLC Pathology Tumor markers Genetics Clinical course Staging Treatment
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

ppt slide no 5 content not found
Slide 6-

ppt slide no 6 content not found
Slide 7-

ppt slide no 7 content not found
Slide 8-

ppt slide no 8 content not found
Slide 9-

ppt slide no 9 content not found
Slide 10-

ppt slide no 10 content not found
Slide 11-

ppt slide no 11 content not found
Slide 12-

ppt slide no 12 content not found
Slide 13-

ppt slide no 13 content not found
Slide 14-

ppt slide no 14 content not found
Slide 15-

ppt slide no 15 content not found
Slide 16-

ppt slide no 16 content not found
Slide 17-

ppt slide no 17 content not found
Slide 18-

ppt slide no 18 content not found
Slide 19-

ppt slide no 19 content not found
Slide 20-

ppt slide no 20 content not found
Slide 21-

ppt slide no 21 content not found
Slide 22-

ppt slide no 22 content not found
Slide 23-

ppt slide no 23 content not found
Slide 24-

ppt slide no 24 content not found
Slide 25-

ppt slide no 25 content not found
Slide 26-

ppt slide no 26 content not found
Slide 27-

ppt slide no 27 content not found
Slide 28-

SCLC, factoids 15 – 25 % of all lung cancers Almost exclusively in smokers Distinguished from NSCLC by: Rapid doubling time High growth fraction Early development of wide-spread mets
Slide 29-

SCLC, factoids (cont’d) Considered highly responsive to “chems and beams” BUT…usually relapses within 2 years despite treatment Overall, only 3 –8 % of all patients survive more than 5 years Most common malignancy associated with Neurologic paraneoplastic syndromes
Slide 30-

SCLC, pathology Most recent (1999) WHO classification Classical small cell carcinoma Large cell neuroendocrine cancer Combined small cell carcinoma with some NSCLC Cells are approx. 2 X’s the size of normal lymphocytes
Slide 31-

SCLC, pathology
Slide 32-

SCLC, pathology
Slide 33-

SCLC, clinical presentation Typically arise centrally Most common presentation is a large hilar mass with bulky mediastinal LAN Common symptoms cough, SOB, wt loss Approx. 70 % with overt mets at presentation Commonly spread to liver, adrenals, bone and brain Can present with paraneoplastic syndome
Slide 34-

SCLC, tumor markers 3 main groups: Neural, Epithelial, Neuroendocrine Epithelial: virtually all SCLCs are immunoreactive for Keratin and Epithelial Membrane Antigen 1 or more markers of Neural/Neuroendocrine differentiation found in approx. 75 % of SCLCs
Slide 35-

SCLC, tumor markers Leads to expression of dopa decarboxylase, calcitonin, neuron-specific enolase, chromogranin A, CD-56 (a neural cell adhesion molecule) gastrin releasing peptide and insulin-like growth hormone Occasionally patients produce antibodies that cross-react with both the SCLC cells and the CNS  cerebellar degeneration syndromes SCLC cells can produce a number of polypeptide hormones including ACTH and Vasopressin
Slide 36-

Neurologic Paraneoplastic Syndromes
Slide 37-

Lung cancer, Paraneoplastic Syndromes
Slide 38-

SCLC, genetics Development of lung cancers occur through stimulation of proliferation and mutagenesis, occurring over YEARS and resulting from exposure to tobacco and other carcinogens
Slide 39-

SCLC, genetics The most common genetics of SCLC are: P53 mutation is present in 75 -90 % Loss of heterozygosity of c-somes 9p and 10q in the majority Deletion of 3p  inactivation of as many as 3 tumor suppressor genes Loss of the retinoblastoma gene function is nearly ubiquitous Activation of telomerase in approx. 90 % (allows cells to divide forever)
Slide 40-

ppt slide no 40 content not found
Slide 41-

ppt slide no 41 content not found
Slide 42-

ppt slide no 42 content not found
Slide 43-

ppt slide no 43 content not found
Slide 44-

ppt slide no 44 content not found
Slide 45-

ppt slide no 45 content not found
Slide 46-

ppt slide no 46 content not found
Slide 47-

ppt slide no 47 content not found
Slide 48-

ppt slide no 48 content not found
Slide 49-

ppt slide no 49 content not found
Slide 50-

ppt slide no 50 content not found
Slide 51-

ppt slide no 51 content not found
Slide 52-

ppt slide no 52 content not found
Slide 53-

ppt slide no 53 content not found
Slide 54-

ppt slide no 54 content not found
Slide 55-

The End Questions?